Drug intelligence / Profile preview

phenylephrine + allopurinol

Development stage: Unknown
Lead developer: Johnson & Johnson Consumer Inc. (J&JCI)
Modality: Small Molecules
Administration: Oral, Intranasal, Intravenous, Ophthalmic

Overview

This is a combination of two separate medications: phenylephrine, a decongestant that narrows blood vessels to reduce swelling and congestion in the nose and sinuses, and allopurinol, a xanthine oxidase inhibitor used to treat gout, kidney stones, and high uric acid levels. When used together, allopurinol may have effects on phenylephrine's vasoconstriction properties. Allopurinol has been shown to prevent nitroglycerin-induced tolerance and intensify endothelium-dependent vasodilation, which could potentially interact with phenylephrine's vasoconstrictive effects.

Targets

ADRA1A (α1A)ADRA1B (α1B)XO (Xanthine Oxidoreductase)

Beyond the preview

Go deeper on phenylephrine + allopurinol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on phenylephrine + allopurinol.

Explore the full profile